News
"Encouraging Results" in Patients With AR Ligand Binding Domain Mutated mCRPC
Daniel Petrylak, MD, discusses radiographic progression-free survival (rPFS) in patients with AR ligand-binding domain mutations in the phase 1/2 study of bavdegalutamide, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer (mCRPC) at the recent 2023 ESMO annual meeting.
Source: Uro/GU Onc Today